Unlocking Superior Weight Loss Outcomes Through Amylin Agonists & Next-Generation Multi-Hormone Therapies
9:30 am - Wednesday 9th December 2026
- Advancing next-generation amylin agonists to enhance appetite control and satiety, unlocking greater weight loss efficacy beyond traditional GLP-1 pathways
- Identifying the patients most likely to benefit from amylin-based therapies by evaluating clinical evidence, response patterns and emerging opportunities for targeted treatment selection
- Optimizing amylin-GLP-1 combination strategies to maximize weight loss outcomes while improving tolerability and supporting long-term treatment adherence
